Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$29.40 and last traded at C$27.24, with a volume of 1404754 shares. The stock had previously closed at C$26.20.
Several analysts have issued reports on the company. Royal Bank of Canada restated a “sector perform” rating and set a C$23.00 price objective on shares of Valeant Pharmaceuticals International in a report on Wednesday, November 8th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a report on Wednesday, November 8th.
The company has a market capitalization of $10,040.00, a price-to-earnings ratio of 5.90 and a beta of -0.67.
TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International (VRX) Sets New 1-Year High at $29.40” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3126445/valeant-pharmaceuticals-international-vrx-sets-new-1-year-high-at-29-40.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.